Pentixapharm Reports the Acquisition of Glycotope’s Target Discovery Business
Shots:
- Pentixapharm has agreed to acquire the Glycotope business unit focusing on target discovery, expanding its IP portfolio
- The acquisition includes Glycotope’s portfolio of preclinical Abs for oncology targets with the potential to be developed into radiopharmaceuticals, laboratories, cell banks, tumor target database & equipment for discovery platform plus various patents, licenses & other assets
- The discovery unit is built upon a technology platform utilized to develop tumor-specific mAbs or fragments targeting tumor-linked carbohydrate structures or protein/carbohydrate combined glycoepitopes (GlycoTargets)
Ref: Pentixapharm | Image: Pentixapharm
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
